Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 12;20(1):229.
doi: 10.1186/s12957-022-02696-x.

Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis

Yonghua Bi #  1 , Dechao Jiao #  1 , Yang Wang  1 , Xinwei Han  2 , Jianzhuang Ren  3
Affiliations

Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis

Yonghua Bi et al. World J Surg Oncol. .

Abstract

Background: Drug-eluting bead transarterial chemoembolization (DEB-TACE) with Callispheres® beads (CB) is currently used in the treatment of hepatocellular carcinoma. However, clinical data regarding DEB-TACE using raltitrexed-eluting CB for gastrointestinal adenocarcinoma liver metastases (GALM) treatment is limited. We aimed to report the preliminary outcomes of DEB-TACE using CB in unresectable GALM patients.

Methods: This retrospective study enrolled unresectable GALM patients who were treated with DEB-TACE using raltitrexed-eluting CB from October 2018 to October 2021. Totally, 25 patients, 18 males and 7 females, mean age 66.8±9.5 years, were continuously enrolled. Postoperative treatment response, survival rates, and complication were calculated during the procedure and follow-up.

Results: Twenty-four patients were technically successful, with a technical success rate of 96.0%. The 3-month overall response rate and disease control rate were 21.7% and 73.9%, and 6-month overall response rate and disease control rate were 30.0% and 65.0%. The median survival time from diagnosis of GALM was 31.3 months. The median survival time and median PFS from first DEB-TACE was 21.3 months (95% confidence interval 9.1-33.5) and 10.7 months (3.7-17.7), respectively. Main adverse events included abdominal pain (36.0%), fever (12.0%), and nausea/vomiting (28.0%) after DEB-TACE. No treatment-related deaths and grade 3 or grade 4 adverse events were observed.

Conclusions: DEB-TACE using raltitrexed eluting CB was demonstrated as a safe and efficient alternative choice for GALM.

Keywords: Callispheres® beads; DEB-TACE; Gastrointestinal adenocarcinoma; Liver metastasis; Raltitrexed.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
A 67-year male treated by CalliSpheres® beads for liver metastases from colonic cancers. a Colonic adenocarcinoma was confirmed pathologically. b, c Computed tomography and magnetic resonance imaging examination on admission revealed multiple intrahepatic metastases (arrows). d–f Computed tomography showed tumors decreased at 1, 3, and 6 months after DEB-TACE
Fig. 2
Fig. 2
A 70-year male treated by CalliSpheres® beads for gastric cancer liver metastases. a, b Preoperative computed tomography examination revealed a large tumor of the right liver (arrows). c The right hepatic artery was superselectively incubated and embolized by drug-loaded beads (arrows). d Tumor staining disappeared after embolization. e, f The right hepatic tumor (arrows) was found to shrink after 1 month’s follow-up
Fig. 3
Fig. 3
A 59-year female treated by CalliSpheres® beads for liver metastases from advanced rectal cancer. a Computed tomography examination revealed multiple intrahepatic metastases in bilateral liver (arrows). b, c Tumor staining (arrows) were shown and the bilateral hepatic arteries were superselectively incubated and embolized, respectively. d Tumor staining disappeared after embolization via CalliSpheres® beads. e, f Disease progression (arrows) was not observed until about one year after first DEB-TACE
Fig. 4
Fig. 4
Follow-up. The median survival time and median PFS from first DEB-TACE was 21.3 months and 10.7 months, respectively
See this image and copyright information in PMC

References

    1. Zoller M. Gastrointestinal tumors: metastasis and tetraspanins. Z Gastroenterol. 2006;44:573–586. doi: 10.1055/s-2006-926795. - DOI - PubMed
    1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi: 10.3322/caac.21338. - DOI - PubMed
    1. Akgul O, Cetinkaya E, Ersoz S, Tez M. Role of surgery in colorectal cancer liver metastases. World J Gastroenterol. 2014;20:6113–6122. doi: 10.3748/wjg.v20.i20.6113. - DOI - PMC - PubMed
    1. Engstrand J, Nilsson H, Stromberg C, Jonas E, Freedman J. Colorectal cancer liver metastases - a population-based study on incidence, management and survival. BMC Cancer. 2018;18:78. doi: 10.1186/s12885-017-3925-x. - DOI - PMC - PubMed
    1. Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42:2212–2221. doi: 10.1016/j.ejca.2006.04.012. - DOI - PubMed